Quality of Life with Advanced Metastatic Prostate Cancer

被引：24
作者：
Resnick, Matthew J. [1 ,2 ]
Penson, David F. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Dept Urol Surg, Ctr Surg Qual & Outcomes Res, Nashville, TN 37232 USA
[2] VA Tennessee Valley Geriatr Res Educ & Clin Ctr G, Nashville, TN 37212 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期
关键词：
Prostate cancer; Metastatic; Castrate-resistant; Quality of life; Functional status; Palliation; ANDROGEN-DEPRIVATION THERAPY; PAINFUL BONE METASTASES; SICKNESS IMPACT PROFILE; MITOXANTRONE PLUS PREDNISONE; HEALTH-STATUS; PHASE-II; RADIONUCLIDE TREATMENT; ASYMPTOMATIC MEN; RANDOMIZED-TRIAL; ZOLEDRONIC ACID;
D O I：
10.1016/j.ucl.2012.07.007
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.
引用
收藏
页码：505 / +
页数：12
相关论文
共 68 条
  • [1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY
    AARONSON, NK
    AHMEDZAI, S
    BERGMAN, B
    BULLINGER, M
    CULL, A
    DUEZ, NJ
    FILIBERTI, A
    FLECHTNER, H
    FLEISHMAN, SB
    DEHAES, JCJM
    KAASA, S
    KLEE, M
    OSOBA, D
    RAZAVI, D
    ROFE, PB
    SCHRAUB, S
    SNEEUW, K
    SULLIVAN, M
    TAKEDA, F
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) : 365 - 376
  • [2] Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer
    Abratt, RP
    Brune, D
    Dirnopoulos, MA
    Kliment, J
    Breza, J
    Selvaggi, FP
    Beuzeboc, P
    Demkow, T
    Oudard, S
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (11) : 1613 - 1621
  • [3] Health-related quality of life among patients with metastatic prostate cancer
    Albertsen, PC
    Aaronson, NK
    Muller, MJ
    Keller, SD
    Ware, JE
    [J]. UROLOGY, 1997, 49 (02) : 207 - 216
  • [4] Impact of Androgen-Deprivation Therapy on Physical Function and Quality of Life in Men With Nonmetastatic Prostate Cancer
    Alibhai, Shabbir M. H.
    Breunis, Henriette
    Timilshina, Narhari
    Johnston, Calvin
    Tomlinson, George
    Tannock, Ian
    Krahn, Murray
    Fleshner, Neil E.
    Warde, Padraig
    Canning, Sarah Duff
    Klotz, Lawrence
    Naglie, Gary
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5038 - 5045
  • [5] [Anonymous], 2011, Campbell-Walsh Urology Tenth Edition
  • [6] The FDA guidance for industry on PROs: the point of view of a pharmaceutical company
    Arpinelli, Fabio
    Bamfi, Francesco
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
  • [7] Long-term effects of androgen deprivation therapy in prostate cancer patients
    Basaria, S
    Leib, J
    Tang, AM
    DeWeese, T
    Carducci, M
    Eisenberger, M
    Dobs, AS
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 56 (06) : 779 - 786
  • [8] THE SICKNESS IMPACT PROFILE - DEVELOPMENT AND FINAL REVISION OF A HEALTH-STATUS MEASURE
    BERGNER, M
    BOBBITT, RA
    CARTER, WB
    GILSON, BS
    [J]. MEDICAL CARE, 1981, 19 (08) : 787 - 805
  • [9] SICKNESS IMPACT PROFILE - VALIDATION OF A HEALTH STATUS MEASURE
    BERGNER, M
    BOBBITT, RA
    POLLARD, WE
    MARTIN, DP
    GILSON, BS
    [J]. MEDICAL CARE, 1976, 14 (01) : 57 - 67
  • [10] Quality of life and pain in advanced stage prostate cancer: Results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone
    Berry, Donna L.
    Moinpour, Carol M.
    Jiang, Caroline S.
    Ankerst, Donna Pauler
    Petrylak, Daniel P.
    Vinson, Lynne V.
    Lara, Primo N.
    Jones, Sharon
    Taplin, Mary E.
    Burch, Patrick A.
    Hussain, Maha H. A.
    Crawford, E. David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2828 - 2835
1234567